Literature DB >> 22705914

Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.

Martha Luevano1, Alejandro Madrigal, Aurore Saudemont.   

Abstract

Natural killer (NK) cells are part of the innate immune system and are an alluring option for immunotherapy due to their ability to kill infected cells or cancer cells without prior sensitization. Throughout the past 20 years, different groups have been able to reproduce NK cell development in vitro, and NK cell ontogeny studies have provided the basis for the establishment of protocols to produce NK cells in vitro for immunotherapy. Here, we briefly discuss NK cell development and NK cell immunotherapy approaches. We review the factors needed for NK cell differentiation in vitro, which stem cell sources have been used, published protocols, challenges and future directions for Good Manufacturing Practice protocols.

Entities:  

Mesh:

Year:  2012        PMID: 22705914      PMCID: PMC4012863          DOI: 10.1038/cmi.2012.17

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  127 in total

1.  Ex-vivo expansion of NK cells: what is the priority--high yield or high purity?

Authors:  Maria Berg; Richard Childs
Journal:  Cytotherapy       Date:  2010-12       Impact factor: 5.414

2.  Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.

Authors:  M C Mingari; C Vitale; C Cantoni; R Bellomo; M Ponte; F Schiavetti; S Bertone; A Moretta; L Moretta
Journal:  Eur J Immunol       Date:  1997-06       Impact factor: 5.532

3.  Different NK cell developmental events require different levels of IL-15 trans-presentation.

Authors:  Gilbert Aaron Lee; Yae-Huei Liou; Szu-Wen Wang; Kai-Liang Ko; Si-Tse Jiang; Nan-Shih Liao
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

4.  The Notch ligands Jagged2, Delta1, and Delta4 induce differentiation and expansion of functional human NK cells from CD34+ cord blood hematopoietic progenitor cells.

Authors:  Rose C Beck; Mallika Padival; David Yeh; Justine Ralston; Kenneth R Cooke; John B Lowe
Journal:  Biol Blood Marrow Transplant       Date:  2009-09       Impact factor: 5.742

5.  IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.

Authors:  Ulrike Koehl; Jan Sörensen; Ruth Esser; Stefanie Zimmermann; Hans Peter Grüttner; Torsten Tonn; Christian Seidl; Erhard Seifried; Thomas Klingebiel; Dirk Schwabe
Journal:  Blood Cells Mol Dis       Date:  2004 Nov-Dec       Impact factor: 3.039

6.  Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.

Authors:  Lisbeth Barkholt; Evren Alici; Reka Conrad; Tolga Sutlu; Mari Gilljam; Birgitta Stellan; Birger Christensson; Hayrettin Guven; Niklas K Björkström; Gunnar Söderdahl; Kerstin Cederlund; Eva Kimby; Johan Aschan; Olle Ringdén; Hans-Gustaf Ljunggren; M Sirac Dilber
Journal:  Immunotherapy       Date:  2009-09       Impact factor: 4.196

7.  Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15.

Authors:  Valarie McCullar; Robert Oostendorp; Angela Panoskaltsis-Mortari; Gong Yun; Charles T Lutz; John E Wagner; Jeffrey S Miller
Journal:  Exp Hematol       Date:  2008-03-04       Impact factor: 3.084

8.  Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity.

Authors:  Petter S Woll; Bartosz Grzywacz; Xinghui Tian; Rebecca K Marcus; David A Knorr; Michael R Verneris; Dan S Kaufman
Journal:  Blood       Date:  2009-04-13       Impact factor: 22.113

9.  Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo.

Authors:  Hollie J Pegram; Jacob T Jackson; Mark J Smyth; Michael H Kershaw; Phillip K Darcy
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

10.  Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15.

Authors:  Massimo Giuliani; Julien Giron-Michel; Simone Negrini; Paola Vacca; Deniz Durali; Anne Caignard; Caroline Le Bousse-Kerdiles; Salem Chouaib; Aurore Devocelle; Rajia Bahri; Antoine Durrbach; Yassine Taoufik; Silvano Ferrini; Michela Croce; Maria Cristina Mingari; Lorenzo Moretta; Bruno Azzarone
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

View more
  27 in total

1.  Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.

Authors:  Guoshuai Cao; Jian Wang; Xiaodong Zheng; Haiming Wei; Zhigang Tian; Rui Sun
Journal:  J Biol Chem       Date:  2015-10-15       Impact factor: 5.157

2.  Impaired NK cell antiviral cytokine response against influenza virus in small-for-gestational-age neonates.

Authors:  Jinrong Li; Hong Li; Huawei Mao; Meixing Yu; Fan Yang; Ting Feng; Yingying Fan; Qiao Lu; Chongyang Shen; Zhongwei Yin; Meng Mao; Wenwei Tu
Journal:  Cell Mol Immunol       Date:  2013-07-22       Impact factor: 11.530

Review 3.  NK cells in immunotolerant organs.

Authors:  Haoyu Sun; Cheng Sun; Zhigang Tian; Weihua Xiao
Journal:  Cell Mol Immunol       Date:  2013-04-08       Impact factor: 11.530

Review 4.  Memory NK cells: why do they reside in the liver?

Authors:  Xiaojun Jiang; Yonglin Chen; Hui Peng; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-08       Impact factor: 11.530

5.  Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features.

Authors:  Meriem Hasmim; Nadine Khalife; Yanyan Zhang; Manale Doldur; Geralidne Visentin; Stéphane Terry; Julien Giron-Michel; Ruoping Tang; François Delhommeau; Nicolas Dulphy; Jean-Henri Bourhis; Fawzia Louache; Salem Chouaib
Journal:  Oncoimmunology       Date:  2017-07-18       Impact factor: 8.110

6.  A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.

Authors:  Sumithira Vasu; Maria Berg; Jan Davidson-Moncada; Xin Tian; Herb Cullis; Richard W Childs
Journal:  Cytotherapy       Date:  2015-11       Impact factor: 5.414

Review 7.  Bringing natural killer cells to the clinic: ex vivo manipulation.

Authors:  Richard W Childs; Maria Berg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

8.  In Vitro Generation of Human NK Cells Expressing Chimeric Antigen Receptor Through Differentiation of Gene-Modified Hematopoietic Stem Cells.

Authors:  Emily Lowe; Laurel C Truscott; Satiro N De Oliveira
Journal:  Methods Mol Biol       Date:  2016

Review 9.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

Review 10.  NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

Authors:  Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Transplant Cell Ther       Date:  2020-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.